发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Effect of sublingual immunotherapy on clinical and laboratory autoimmunity. 舌下免疫疗法对临床和实验室自身免疫的影响
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI: 10.2217/imt-2023-0231
Andrzej Bozek, Szymon Mućka, Martyna Miodonska, Anna Zlik, Magdalena Mroz-Dybowska
{"title":"Effect of sublingual immunotherapy on clinical and laboratory autoimmunity.","authors":"Andrzej Bozek, Szymon Mućka, Martyna Miodonska, Anna Zlik, Magdalena Mroz-Dybowska","doi":"10.2217/imt-2023-0231","DOIUrl":"10.2217/imt-2023-0231","url":null,"abstract":"<p><p><b>Background:</b> There still are few data on the long-term safety of sublingual immunotherapy (SLIT). The aim of this study was to assess the appearance of autoimmune diseases in patients before and after SLIT. <b>Materials & methods:</b> New cases of autoimmune diseases were monitored. Patients in the SLIT group (n = 816) were compared with controls (n = 1096). <b>Results:</b> The new incidences of autoimmune diseases in the SLIT group were lower compared with the control group: 18 (2.2%) versus 58 (5.3%); p < 0.05. Systemic lupus erythematosus, psoriasis and Hashimoto appeared much more often in the control group. <b>Conclusion:</b> SLIT had no significant effect on the induction of autoimmune diseases.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"235-241"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy. 洞察肿瘤相关三级淋巴结构在癌症免疫疗法中的成熟异质性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0196
Wenhao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hailiang Zhang, Dingwei Ye
{"title":"Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy.","authors":"Wenhao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hailiang Zhang, Dingwei Ye","doi":"10.2217/imt-2023-0196","DOIUrl":"10.2217/imt-2023-0196","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"131-134"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review. 银屑病关节炎中甲氨蝶呤与口服改变病情抗风湿药的联合治疗：系统综述。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0139
Tyng-Shiuan Hsieh, Tsen-Fang Tsai
{"title":"Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review.","authors":"Tyng-Shiuan Hsieh, Tsen-Fang Tsai","doi":"10.2217/imt-2023-0139","DOIUrl":"10.2217/imt-2023-0139","url":null,"abstract":"<p><p><b>Background:</b> Oral conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), especially methotrexate, are the cornerstone of treating psoriatic arthritis (PsA). The use of csDMARDs with biologics has increased their efficacy in psoriasis. However, the combination of two oral DMARDs in patients with PsA has not been adequately reviewed. In this study, we explore the combinational use of methotrexate with DMARDs in PsA patients. <b>Materials & methods:</b> A review was conducted using Medline (PubMed), Embase, Web of Science and the Cochrane Library, covering articles up to February 2023. <b>Results & conclusion:</b> Nine studies comprising 1993 participants were included. The evidence supporting combination therapy remains limited. Combinational therapy could be considered in patients with inadequate response to monotherapy or no access to biologics.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"115-130"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives. 头颈部鳞状细胞癌的免疫疗法：现状与展望。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI: 10.2217/imt-2023-0174
Amaury Daste, Mathieu Larroquette, Nyere Gibson, Matthieu Lasserre, Charlotte Domblides
{"title":"Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.","authors":"Amaury Daste, Mathieu Larroquette, Nyere Gibson, Matthieu Lasserre, Charlotte Domblides","doi":"10.2217/imt-2023-0174","DOIUrl":"10.2217/imt-2023-0174","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatment of HNSCCs, mainly in combination with standard chemotherapy. This review focuses on the results of the main phase III studies evaluating ICIs in recurrent or metastatic HNSCCs. The efficacy and indications according to the PD-L1 status, the main predictive biomarker, are discussed. The results of trials assessing ICI efficacy for locally advanced disease, including the neoadjuvant setting are also discussed. Finally, therapeutic combinations that are potential treatments for HNSCCs, including ICIs and targeted therapies such as anti-EGFR agents, are presented.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"187-197"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of filgotinib in ulcerative colitis and Crohn's disease. 非戈替尼在溃疡性结肠炎和克罗恩病中的作用。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-11-27 DOI: 10.2217/imt-2023-0116
Jacopo Fanizza, Ferdinando D'Amico, Gaetano Lauri, Samuel J Martinez-Dominguez, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese
{"title":"The role of filgotinib in ulcerative colitis and Crohn's disease.","authors":"Jacopo Fanizza, Ferdinando D'Amico, Gaetano Lauri, Samuel J Martinez-Dominguez, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese","doi":"10.2217/imt-2023-0116","DOIUrl":"10.2217/imt-2023-0116","url":null,"abstract":"<p><p>Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD). The purpose of this review is to summarize the available data regarding filgotinib in the management of UC and CD. We used Pubmed, Embase and clinicaltrials.gov websites to search all available data and currently ongoing studies regarding the efficacy and safety of filgotinib in inflammatory bowel diseases. Filgotinib is an effective and safe drug for the management of biologic-naive and biologic-experienced patients with moderate-to-severe UC. The same efficacy results have not been achieved in CD.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"59-74"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138440581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation and resolve: unlocking the synergistic potential of radioimmunotherapy in advanced lung cancer management. 放射与决心：释放放射免疫疗法在晚期肺癌治疗中的协同潜力。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-06 DOI: 10.2217/imt-2023-0268
Yi Zhang, Zheng Li, Bingwen Zou
{"title":"Radiation and resolve: unlocking the synergistic potential of radioimmunotherapy in advanced lung cancer management.","authors":"Yi Zhang, Zheng Li, Bingwen Zou","doi":"10.2217/imt-2023-0268","DOIUrl":"10.2217/imt-2023-0268","url":null,"abstract":"<p><p>Plain language summary This editorial talks about combining radiation therapy (using high-energy rays to kill cancer cells) and immunotherapy (boosting the body's immune system to fight cancer) to treat advanced lung cancer. When used together, these therapies can work better to kill more cancer cells and help patients live longer. But, there's still a lot we don't know. For instance, we need to figure out the best timing and doses for these treatments, and which patients will benefit the most. The article stresses that more research is needed to answer these questions and make this combined treatment a more effective option for advanced lung cancer patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"55-58"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report. 多线化疗失败后使用托利帕利单抗和福罗替尼治疗结直肠癌：病例报告。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0235
Ling-Zhijie Kong, Ying Zheng, Kaichun Li
{"title":"Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report.","authors":"Ling-Zhijie Kong, Ying Zheng, Kaichun Li","doi":"10.2217/imt-2023-0235","DOIUrl":"10.2217/imt-2023-0235","url":null,"abstract":"<p><p>The options for treating metastatic colorectal cancer are limited after failure of second-line chemotherapy. In this case report, we present the outcome of a 59-year-old male patient who underwent radical resection for rectal cancer in November 2018 and hepatectomy for liver metastasis in January 2021. His metastatic rectal cancer presented a remarkable response to the combination of fruquintinib and toripalimab after the failure of multiline chemotherapies. The patient achieved partial response within 3 months and clinical complete response of pulmonary masses within 12 months. As of now, the patient maintains a good quality of life, and the progression-free survival has been more than 17 months. In conclusion, the combination of fruquintinib and PD-1 inhibitors can improve the prognosis of metastatic colorectal cancer.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"107-114"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging findings can't mean everything in the era of immunotherapy: a case report and literature review. 免疫疗法时代，成像结果不能代表一切：病例报告和文献综述。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0158
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
{"title":"Imaging findings can't mean everything in the era of immunotherapy: a case report and literature review.","authors":"Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu","doi":"10.2217/imt-2023-0158","DOIUrl":"10.2217/imt-2023-0158","url":null,"abstract":"<p><p>Immune-checkpoint inhibitors (ICIs) play an important role in the treatment of cancers. However, immunotherapy can also induce atypical response patterns, including pseudoprogression, which is challenging to clinicians. We reported a case of non-small-cell lung cancer showing so-called pseudoprogression during the treatment of pembrolizumab and the patient benefited clinically from continued treatment with ICIs. Therefore, beside imaging evaluation, the assessment of Eastern Cooperative Oncology Group performance status score, numerical rating scale score of cancer pain, tumor markers levels, and neutrophil-to-lymphocyte ratio should be used for response evaluation of tumors in the era of immunotherapy. And more accurate evaluation methods and reliable information are urgently needed to better understand the pseudoprogression.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"99-106"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement. 一种三特异性抗体通过 CD3/CD28 共同参与诱导强效的肿瘤定向 T 细胞活化和抗肿瘤活性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI: 10.2217/imt-2023-0256
Li Chen, Wenjing Qian, Fangfang Pan, Debin Li, Weiwei Yu, Li Tong, Yingying Yang, Qiming Xu, Jianfeng Ding, Ruixue Dai, Weiwei Xian, Xufeng Zhu, Pu Ren, Huaxing Zhu
{"title":"A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement.","authors":"Li Chen, Wenjing Qian, Fangfang Pan, Debin Li, Weiwei Yu, Li Tong, Yingying Yang, Qiming Xu, Jianfeng Ding, Ruixue Dai, Weiwei Xian, Xufeng Zhu, Pu Ren, Huaxing Zhu","doi":"10.2217/imt-2023-0256","DOIUrl":"10.2217/imt-2023-0256","url":null,"abstract":"<p><p><b>Aim:</b> A novel CD19xCD3xCD28 trispecific antibody with a tandem single-chain variable fragments (scFv) structure was developed for the treatment of B-cell malignancies. <b>Methods:</b> The trispecific antibody in inducing tumor-directed T-cell activation and cytotoxicity was evaluated <i>in vitro</i> and <i>in vivo</i> and compared with its bispecific counterpart BiTE-CD19xCD3 lacking a CD28-targeting domain. <b>Results:</b> The trispecific antibody with a co-stimulatory domain exhibited augmented T-cell activation and memory T-cell differentiation capability and it induced faster tumor cell lysis than the bispecific antibody. RNAseq analysis revealed that the trispecific antibody modulates CD3/TCR complex-derived signal and upregulates antiapoptotic factors to influence the survival of T cells. <b>Conclusion:</b> By CD3/CD28 co-engagement, the trispecific antibody demonstrated its advantages in T-cell immunity and potential use as a more powerful and long-lasting T-cell engager.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"143-159"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer. ICAM2 与树突状细胞免疫疗法治疗癌症的良好预后有关。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI: 10.2217/imt-2021-0097
Saulo Fm da Silva, Eddie Fc Murta, Márcia A Michelin
{"title":"ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer.","authors":"Saulo Fm da Silva, Eddie Fc Murta, Márcia A Michelin","doi":"10.2217/imt-2021-0097","DOIUrl":"10.2217/imt-2021-0097","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the behavior of adhesion molecules ICAM-1 and ICAM-2 in dendritic cell (DC) immunotherapy. <b>Materials & methods:</b> 88 female Balb/c mice were divided into experimental groups. Tumors and lymph nodes were evaluated 7 and 14 days after immunotherapy. <b>Results:</b> Higher mean fluorescence intensity of ICAM-1 in the lymph nodes and tumors in the tumor group at 14 days was observed. Higher mean fluorescence intensity of ICAM-2 in the tumor DC vaccine group was observed after 14 days. A positive correlation was observed in the lymph nodes with ICAM-1 against tumoral volume in the tumor group. A negative correlation was found between ICAM-2 and tumoral volume in the lymph nodes of the tumor group. <b>Conclusion:</b> An increase in ICAM-2 in tumor DC vaccine and a decrease in ICAM-1 suggests the DC vaccine positively influences the immune system and that ICAM-2 could be a marker of good prognosis.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"173-185"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信